Download Files:
Products Details
Product Description
– MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects[1].
Web ID
– HY-156119
Shipping
– Room temperature
Molecular Formula
– C20H18N4O5
References
– [1]Oh J H, et al. Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist[J]. ACS Pharmacology & Translational Science, 2023.. . .
Molecular Weight
– 394.38
SMILES
– O=C(OC)/C=C/C(N1C)=NC(N(CC#CC2=CC=CC(O)=C2)C(N3C)=O)=C1C3=O
Clinical Information
– No Development Reported
Research Area
– Cancer; Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– Mixed Lineage Kinase;Necroptosis
Pathway
– Apoptosis;MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
